Literature DB >> 22367751

Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura.

Spero R Cataland, Flora Peyvandi, Pier M Mannucci, Bernhard Lämmle, Johanna A Kremer Hovinga, Samuel J Machin, Marie Scully, Gail Rock, James C Gilbert, Shangbin Yang, Haifeng Wu, Bernd Jilma, Paul Knoebl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22367751     DOI： 10.1002/ajh.23106

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  22 in total

Review 1.  Modulation of the Coagulation Cascade Using Aptamers.

Authors:  Rebecca S Woodruff; Bruce A Sullenger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-27       Impact factor: 8.311

2.  A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity.

Authors:  Raffaella Rossio; Luca Andrea Lotta; Silvia Pontiggia; Nicolò Ghiringhelli Borsa; Isabella Garagiola; Gianluigi Ardissino; Danijela Mikovic; Massimo Cugno; Flora Peyvandi
Journal:  Haematologica       Date:  2014-11-07       Impact factor: 9.941

3.  Degradation of platelet-von Willebrand factor complexes by plasmin: an alternative/backup mechanism to ADAMTS13.

Authors:  Anil K Chauhan
Journal:  Circulation       Date:  2014-01-21       Impact factor: 29.690

Review 4.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

Review 5.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

6.  Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura.

Authors:  Liang Zheng; Yingying Mao; Mohammad S Abdelgawwad; Nicole K Kocher; Mandy Li; Xiangrong Dai; Benjamin Li; X Long Zheng
Journal:  Blood Adv       Date:  2016-11-29

Review 7.  von Willebrand factor: an emerging target in stroke therapy.

Authors:  Simon F De Meyer; Guido Stoll; Denisa D Wagner; Christoph Kleinschnitz
Journal:  Stroke       Date:  2011-12-15       Impact factor: 7.914

8.  Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab.

Authors:  Kazuya Sakai; Tatsuhiko Someya; Kaori Harada; Hideo Yagi; Taei Matsui; Masanori Matsumoto
Journal:  Haematologica       Date:  2019-12-19       Impact factor: 9.941

9.  Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

Authors:  Lingegowda S Mangala; Hongyu Wang; Dahai Jiang; Sherry Y Wu; Anoma Somasunderam; David E Volk; Ganesh L R Lokesh; Xin Li; Sunila Pradeep; Xianbin Yang; Monika Haemmerle; Cristian Rodriguez-Aguayo; Archana S Nagaraja; Rajesha Rupaimoole; Emine Bayraktar; Recep Bayraktar; Li Li; Takemi Tanaka; Wei Hu; Cristina Ivan; Kshipra M Gharpure; Michael H McGuire; Varatharasa Thiviyanathan; Xinna Zhang; Sourindra N Maiti; Nataliya Bulayeva; Hyun-Jin Choi; Piotr L Dorniak; Laurence Jn Cooper; Kevin P Rosenblatt; Gabriel Lopez-Berestein; David G Gorenstein; Anil K Sood
Journal:  JCI Insight       Date:  2016-10-20

10.  Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.

Authors:  Mohammad S Abdelgawwad; Wenjing Cao; Liang Zheng; Nicole K Kocher; Lance A Williams; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.